Regarding PDD, from the CC transcript...extremely positive comments and additional details from Dr.Missling.
Robert LeBoyer -- Ladenburg Thalmann -- Analyst
Just that had to do with the presentation of the full slide --
Christopher Missling -- President and Chief Executive Officer
All right. The PDD. Right. Yeah, excellent question.
So the CTAD was really focused on the dementia portion of the study, the dementia portion of the PDD study. What is now -- will come up and we will present that in a proper fashion, either at a conference or in a peer-reviewed form or in a webinar or that fashion. We will provide the entire data of all the other measures of the CDR system which are many more than the ones presented at CTAD, which also was a very short time frame of presentation of only 10 minutes, so we have to factor that in and it will also include the actigraphy data and other data related to Parkinson's disease. So this will be something which we are also planning to present on a relatively short notice.
And so in order to have that full picture of PDD and the same applies here, this data, this aggregated data will be put in front of the FDA and to seek guidance in order to design a pivotal study in PDD.
Considering the excitement about data to be released and urgency with which he is meeting with FDA, we can pretty much conclude that the data is great and met the endpoints that were set forth during the onset of the trials.
-vg_future
